# Efficacy/Safety of DP-R207 Tablet Versus CRESTOR Tablet in Patients With Primary Hypercholesterolemia

> **NCT02445352** · PHASE3 · COMPLETED · sponsor: **Alvogen Korea** · enrollment: 379 (actual)

## Conditions studied

- Primary Hypercholesterolemia

## Interventions

- **DRUG:** Rosuvastatin 5mg
- **DRUG:** DP-R207 5/10mg
- **DRUG:** Rosuvastatin 10mg
- **DRUG:** DP-R207 10/10mg
- **DRUG:** Rosuvastatin 20mg
- **DRUG:** DP-R207 20/10mg
- **DRUG:** Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg)
- **DRUG:** Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg)
- **DRUG:** Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg)

## Key facts

- **NCT ID:** NCT02445352
- **Lead sponsor:** Alvogen Korea
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2015-01
- **Final completion:** 2015-03
- **Target enrollment:** 379 (ACTUAL)
- **Last updated:** 2015-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02445352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02445352, "Efficacy/Safety of DP-R207 Tablet Versus CRESTOR Tablet in Patients With Primary Hypercholesterolemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02445352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*